Stoke Therapeutics (STOK) Total Non-Current Liabilities (2018 - 2026)

Stoke Therapeutics' Total Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $7.6 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 37.39% year-over-year to $7.6 million in Q1 2026; TTM through Mar 2026 was $7.6 million, a 37.39% decrease from a year earlier, with the FY2025 full-year figure at $8.1 million, up 226.96% from the prior year.
• Total Non-Current Liabilities fell to $7.6 million in Q1 2026 per STOK's latest filing, from $8.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $53.1 million in Q1 2022 and bottomed at $2.5 million in Q4 2024.
• The 5-year median for Total Non-Current Liabilities is $29.2 million (2024), against an average of $27.1 million.
• Across the five-year window, Total Non-Current Liabilities jumped 15832.73% in 2022 and tumbled 93.47% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $39.8 million in 2022, then decreased by 4.69% to $38.0 million in 2023, then tumbled by 93.47% to $2.5 million in 2024, then surged by 226.96% to $8.1 million in 2025, then retreated by 6.27% to $7.6 million in 2026.
• Per Business Quant, the three latest STOK Total Non-Current Liabilities figures stand at $7.6 million (Q1 2026), $8.1 million (Q4 2025), and $10.4 million (Q3 2025).